Exemption to SII pneumococcal vaccine from price control for 5 years: NPPA

In a major relief to Serum Institute of India, the drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has decided to grant exemption to Serum Institute of India's (SII) indigenously developed pneumococcal polysaccharide conjugate vaccine against pneumonia from price fixation for a period of five years from the date of commencement of its commercial production in the country, subject to it being co-terminus with the duration of the Indian Patent.

For more information, check out the full story on the link below:

Exemption To SII Pneumococcal Vaccine From Price Control For 5 Years: NPPA